Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. (IOVA) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001425205 · IOVA · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001425205 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2010. As a Healthcare sector company with CIK 0001425205, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Iovance Biotherapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Iovance Biotherapeutics, Inc. 10-K was filed on 2026-02-24 for fiscal year ending 2026. Historical IOVA 10-K annual reports are available from 2008 through 2026.
Investors researching Iovance Biotherapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
IOVA SEC Filings · 8 questionsIovance Biotherapeutics, Inc. (IOVA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Iovance Biotherapeutics, Inc.'s CIK is 0001425205.